14th April 2026

British National Formulary

This update contains 12 significant changes, 1 dose change, 1 classification change, 1 new monograph and 1 deleted monograph. 

Significant Changes:  

• Chikungunya vaccine (live) (IXCHIQ®): updates to restrictions of use following safety review [MHRA/CHM advice]. 

• Chronic heart failure: updated guidance on management. 

• GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases [MHRA/CHM advice] (advice in dulaglutide, liraglutide, semaglutide, tirzepatide; see example in dulaglutide). 

• Immunisation schedule: updated guidance for immunisation against respiratory syncytial virus. 

• Improving information supplied with Gabapentinoids (pregabalin/gabapentin), Benzodiazepines and Z-drugs [MHRA/CHM advice] (advice in gabapentin, pregabalin, all benzodiazepines, eszopiclone, zolpidem tartrate, zopiclone; see example in diazepam). 

• Isotretinoin: changes to prescribing guidance and additional risk minimisation measures [MHRA/CHM advice]. 

• Omeprazole: new advice in cautions and renal impairment for oral suspension. 

• Respiratory syncytial virus immunisation: updated guidance. 

• Semaglutide (Wegovy®, Ozempic®, and Rybelsus®): risk of non-arteritic anterior ischaemic optic neuropathy (NAION) [MHRA/CHM advice]. 

• Semaglutide (Wegovy®): update to indications and dosing for weight management. 

• urea (13C): name change to urea (13C). 

• Vitamins: updated guidance for management of vitamin D deficiency. 

Dose Changes:  

• Respiratory syncytial virus (RSV) vaccine (Abrysvo®) [update to indications and dose]. 

Classification Changes:  

• Selexipag [primary classification changed to Prostaglandins and related substances]. 

New Monographs:  

• Lyfnua® [gefapixant]. 

Deleted Monographs: Exenatide; Insulin glargine with lixisenatide; Lixisenatide. 

14th April 2026

BNF for Children

This update contains 7 significant changes.

Significant Changes:

• GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases [MHRA/CHM advice] (advice in dulaglutide, liraglutide, semaglutide; see example in dulaglutide).
• Improving information supplied with Gabapentinoids (pregabalin/gabapentin), Benzodiazepines and Z-drugs [MHRA/CHM advice] (advice in gabapentin, all benzodiazepines; see example in diazepam).
• Isotretinoin: changes to prescribing guidance and additional risk minimisation measures [MHRA/CHM advice].
• Omeprazole : new advice in cautions and renal impairment for oral suspension.
• Semaglutide (Wegovy®, Ozempic®, and Rybelsus®): risk of non-arteritic anterior ischaemic optic neuropathy (NAION) [MHRA/CHM advice].
• urea (13C): name change to urea (¹³C).
• Vitamins: updated guidance for management of vitamin D deficiency.

14th April 2026

Psychotropic Drug Directory

This update contains changes to 9 records.

Revisions: 1.14 Depression

Minor updates: 2.2.1.2 Specific antipsychotic switches; 2.2.1.5 LAI and Depot injections; 2.2.7 Switching or discontinuing antidepressants; 3.2 Cardiovascular (CV) disease; 3.3 Diabetes; 3.6 Hepatic impairment; 3.8 Parkinson’s disease (PD); 7.0 Psychotropic drugs.

14th April 2026

Palliative Care Formulary

This update contains 2 revised monographs.

The following monographs have been partially updated: Ketamine; Proton pump inhibitors.

14th April 2026

Stockley’s Herbal Medicines Interactions

Minor updates to the content on St John’s wort, pomelo, pomegranate, and omega-3 fatty acids have been made. Pharmacopoeial information has also been updated.

14th April 2026

AHFS Drug Information

This update contains 7 new monographs and 32 revised monographs.

New monographs: Carbachol and Brimonidine Tartrate; Copper Histidinate; Narsoplimab-wuug; Tradipitant.

Revised monographs: amLODIPine; Captopril; Cefuroxime; Clevidipine; cloNIDine; Codeine; Corticotropin, Repository; Cosibelimab-ipdl; Dasiglucagon Hydrochloride; Digoxin; dilTIAZem Hydrochloride; Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed/Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Donidalorsen Sodium; Elamipretide Hydrochloride; Eptifibatide; Felodipine; Flunisolide (Oral Inhalation); Furosemide; guanFACINE Hydrochloride; Haemophilus b Vaccine; Heparin Sodium; Hepatitis B Vaccine; Imlunestrant Tosylate; Lisinopril; Lisocabtagene Maraleucel; Losartan Potassium; MetroNIDAZOLE (systemic); Nemolizumab-ilto; NIFEdipine; Olmesartan Medoxomil; Paltusotine Hydrochloride; Pomalidomide; PONATinib Hydrochloride; Pralsetinib; Ribavirin; Risankizumab-rzaa; Sacubitril and Valsartan; SITagliptin; Sodium Nitroprusside; Tetanus and Diphtheria Toxoids Adsorbed; Tirofiban Hydrochloride; Varenicline Tartrate; Verapamil Hydrochloride; Zanubrutinib; Zenocutuzumab-zbco.